Combination therapy with relatlimab and nivolumab enhances treatment-free survival in advanced melanoma, offering promising ...

The study evaluated lifileucel in patients 18 years and older with unresectable or metastatic melanoma (stage IIIc or IV) who ...

The US FDA has approved imlunestrant (Inluriyo) for the treatment of adult patients with estrogen receptor (ER)-positive, ...

The JAVELIN Bladder 100 trial established avelumab (Bavencio) as a standard switch maintenance therapy, according to Grivas.

Iberdomide is a member of a new drug class in myeloma known as CELMoD agents, which build on the established platform of ...

Preliminary Kaplan-Meier analyses, presented at the American Association for Cancer Research (AACR) 7th Biennial Special ...

Daratumumab-based regimens show significant clinical benefits for newly diagnosed, transplant-ineligible multiple myeloma ...

FDA lifts REMS program for vandetanib, affirming safety in thyroid cancer treatment as healthcare providers ensure effective ...

Since the development of crizotinib (Xalkori), oncologists can now choose from an array of later-generation drugs in the ...

In an interview with Targeted Oncology, Paula Rodriguez Otero, MD, PhD, consultant and deputy professor at the University of Navarra, discusses the efficacy of linvoseltamab (Lynozific) in high-risk ...

IMNN-001 demonstrated positive shifts in the tumor microenvironment (TME) along with a favorable safety profile when used for ...

The MEDALIST trial was a phase 3 study with patients with ESA-refractory, low-risk MDS who require transfusions. In this ...